You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice
  1. Donald Richards1,
  2. Si G Li2,
  3. Thomas Anderson1,
  4. Marc Monte3,
  5. Brian Ulrich1,
  6. David A Smith4,
  7. Mahesh Seetharam5,
  8. Paul Kaywin6,
  9. Ray Page7,
  10. Kimary Kulig8,
  11. Cory Batenchuk8 and
  12. Maen Hussein9
  1. Aff1 grid.420754.00000000404125468US Oncology Houston TX USA
  2. Aff2 BioStat Solutions, Inc. Frederick MD USA
  3. Aff3 grid.477069.bClopton Clinic of Jonesboro, Inc. Jonesboro AR USA
  4. Aff4 grid.492876.60000 0004 0637 2702Compass Oncology Vancouver WA USA
  5. Aff5 grid.492893.d0000 0004 0481 639XArizona Oncology Phoenix AZ USA
  6. Aff6 grid.418212.c0000 0004 0465 0852Miami Cancer Institute, Baptist Health Medical Group Miami FL USA
  7. Aff7 grid.477919.5The Center for Cancer and Blood Disorders Fort Worth TX USA
  8. Aff8 grid.419971.3Bristol-Myers Squibb Princeton NJ USA
  9. Aff9 grid.428633.8Florida Cancer Specialists Tavares FL USA

https://doi.org/10.1186/2051-1426-3-S2-P170

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    The majority of lung cancer in the U.S. is treated in the community. A prospective cohort study of stage IV NSCLC and extensive disease (ED) SCLC is being conducted in 70 U.S. community practices to assess outcomes during the pre- and post-immunotherapy eras of lung cancer treatment. This analysis focuses on characteristics of the rarer SCLC subset in the pre-immunotherapy era.

    Methods

    ED SCLC patients, at any point in their care, with documented dates of diagnosis and prior treatment are eligible. Patients are followed prospectively for 36 months or until death, with data abstraction from medical records. Archival tumor tissue (formalin-fixed paraffin-embedded) slides are used to measure PD-L1 protein expression with a validated, automated immunohistochemistry (IHC) assay from Dako using the 28-8 antibody. Expression levels of tumor cell membrane staining at any intensity were defined for ≥1% and ≥ 5% of 100 assessable tumor cells.

    Results

    Data from 268 cases with complete records are reported. At enrollment, 95% were ever smokers, 53% female, and 26% ECOG performance status (PS) 2 or 3. The most prevalent sites of metastases were liver (34%), bone (32%), and brain (21%). History of a specific autoimmune condition was present in 8% of cases. The median overall survival from diagnosis with extensive disease will be reported. PD-L1 IHC was performed on 96/268 patients with available tissue and was evaluable in 87/96 cases. PD-L1 was expressed at ≥1% for 13 cases (15%) and ≥5% for 2 (2%) cases. Of these, 85 had hematoxylin and eosin (H&E) staining performed showing tumor inflammation in 62% and tumor necrosis in 41% of cases. An intra-tumoral inflammatory infiltrate of ≥10% was observed in 49% of cases and is associated with PD-L1 expression at ≥1% (P < 0.003).

    Conclusion

    Many immunotherapy clinical trials exclude patients with active or untreated brain metastases and patients receiving treatment for autoimmune disease, yet a substantial proportion of community-based SCLC patients present with these attributes. PD-L1 expression levels in SCLC appear lower than those previously reported in NSCLC. The role of PD-L1 and other tumor and blood-based markers as prognostic or predictive for SCLC outcomes will be investigated in this ongoing study.

    View this table:

    Summary of clinical attributes and PD-L1 Expression in SCLC